P650: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES

P650: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES

Bibliographic Details
Main Authors:	K. Linton, G. P. Collins, D. El-Sharkawi, R. Mous, F. Forconi, M. Tan, S. Nandakumar, E. Meredith, K. L. Jameson, S. G. Injac, J. Doorduijn
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845484.57038.64

Similar Items

PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
by: Kim Linton, et al.
Published: (2023-08-01)

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
by: Kim Linton, et al.
Published: (2023-08-01)

P649: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN-CLASS ORAL BTK DEGRADER WITH IMID-LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES
by: A. Mato, et al.
Published: (2022-06-01)

Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors
by: Nkolika Nwankwo, et al.
Published: (2024-01-01)

“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors
by: Brian T. Grainger, et al.
Published: (2024-11-01)

MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
by: O Al-Sawaf, et al.
Published: (2023-10-01)

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
by: Raji E Joseph, et al.
Published: (2024-12-01)

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY
by: L. E. Roeker, et al.
Published: (2022-06-01)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

Monoclonal-Antibody-Based Immunoassays for the Mycotoxins NX-2 and NX-3 in Wheat
by: Chris M. Maragos, et al.
Published: (2024-05-01)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
by: Vivian Changying Jiang, et al.
Published: (2023-02-01)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
by: Raji E Joseph, et al.
Published: (2020-11-01)

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
by: Lydia Scarfò, et al.
Published: (2023-08-01)

PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL
by: A. Sharp, et al.
Published: (2022-06-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
by: Phillip L.R. Nicolson, et al.
Published: (2018-12-01)

Early Islamic art, 650-1100 /
by: 203684 Grabar, Oleg
Published: (c200)

Islamic art and architecture 650-1250 /
by: 279798 Ettinghausen, Richard, et al.
Published: (2001)

BTK, the new kid on the (oncology) block?
by: Emanuela Grassilli, et al.
Published: (2022-08-01)

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.
by: Flossmann, O, et al.
Published: (2009)

Exposure to Therapeutic BTK Inhibitors Induces Phenocopying of Btk29A Mutants in the Fruit Fly Drosophila melanogaster
by: Noriko Hamada-Kawaguchi, et al.
Published: (2023-06-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
by: Xiaoyu Feng, et al.
Published: (2023-08-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
by: Ekaterina Likold, et al.
Published: (2023-08-01)

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
by: Eyre, T, et al.
Published: (2017)

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
by: John C. Byrd, et al.
Published: (2023-08-01)

BTK inhibition in myeloma: targeting the seed and the soil.
by: Edwards, C
Published: (2012)

The CLL hunters: finally, BTK got arrested
by: Loic Ysebaert
Published: (2025-01-01)

Low-dose Btk inhibitors: an ‘aspirin’ of tomorrow?
by: Bernard Payrastre, et al.
Published: (2021-01-01)

Integrin Signaling Shaping BTK-Inhibitor Resistance
by: Laura Polcik, et al.
Published: (2022-07-01)

Sanadset 650K: Data on Hadith narrators
by: Mohammed Mghari, et al.
Published: (2022-10-01)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2021-02-01)

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
by: Wendy B.C. Stevens, et al.
Published: (2020-02-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Treatment of relapsed and refractory multiple myeloma
by: Pieter Sonneveld, et al.
Published: (2016-08-01)

Treatment of relapsed and refractory multiple myeloma
by: Pieter Sonneveld, et al.
Published: (2016-04-01)

Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
by: Jingshi Wang, et al.
Published: (2020-05-01)